No profile data available.
Coherus Oncology, Inc. (CHRS) is a healthcare company in the blood disorder treatment drugs industry, based in Redwood City, United States, with about 144 full-time employees.
It reported revenue of $42.17 million for fiscal year 2025, down 84.2% from fiscal year 2024, and net income of $168.02 million. Its market capitalization was $165.32 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
Coherus Oncology reported $42.17 million in revenue for fiscal year 2025, down 84.2% from $266.96 million in fiscal year 2024.
$165.32 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood disorder treatment drugs) include Geron Corporation (GERN), Rocket Pharmaceuticals, Inc. (RCKT), Keros Therapeutics, Inc. (KROS), Rallybio Corporation (RLYB).